A new systematic review of 32 clinical practice guidelines (CPGs) for severely ill COVID-19 patients reveals that most were of poor quality, with few reporting funding sources or conflicts of interest, employing a methodologist, describing a search strategy or study selection process, or synthesizing evidence.The review, published in JAMA Network Open, was conducted by a team led by University of Toronto researchers from Dec 14, 2020, to Feb 28, 2021.The team evaluated clinical guidelines on drug treatments for hospitalized COVID-19 patient against the National Academy of Medicine's (NAM's) eight criteria for trustworthiness.